What's Happening?
Nona Biosciences has entered a research collaboration with the Medical University of Vienna to advance the development of fully human antibodies for infectious diseases. The partnership grants the Ignaz Semmelweis Institute access to Nona's H2L2 Harbour
Mice® technology, which generates fully human monoclonal antibodies. This collaboration aims to enhance research and development programs targeting viral infections, leveraging the expertise of Prof. Florian Krammer and his team. The H2L2 Harbour Mice® platform is noted for its versatility in producing antibodies for various applications, including bispecific antibodies and CAR-T therapies.
Why It's Important?
This collaboration represents a significant step in the development of advanced therapeutic solutions for infectious diseases, particularly in the context of pandemic preparedness. By utilizing Nona's cutting-edge technology, the partnership aims to accelerate the discovery of effective antiviral therapies, potentially leading to breakthroughs in treatment options for viral infections. The initiative also highlights the importance of international cooperation in biotechnological research, combining resources and expertise to address global health challenges. The success of this collaboration could pave the way for new therapeutic approaches and strengthen the global response to future pandemics.
